Bioceltix S.A. (WSE:BCX)
Poland · Delayed Price · Currency is PLN 81.50
-0.40 (-0.49%)
May 21, 2026, 5:00 PM CET
Bioceltix Company Description
Bioceltix S.A. engages in the development of stem cell-based biopharmaceuticals for veterinary use.
Its products include BCX-CM-J, a stem-cell based biological drug for the treatment of degenerative joint lesions in dogs; BCX-CM-AD, a biological drug candidate based on allogeneic stem cells for the treatment of atopic dermatitis in dogs; and BCX-EM, a biological drug candidate based on allogeneic mesenchymal stem cells for the treatment of arthritis in horses.
The company was incorporated in 2018 and is based in Wroclaw, Poland.
Bioceltix S.A.
| Country | Poland |
| Founded | 2016 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 41 |
| CEO | Lukasz Bzdzion |
Contact Details
Address: Building III Wroclaw Poland | |
| Phone | 48 71 880 8771 |
Stock Details
| Ticker Symbol | BCX |
| Exchange | Warsaw Stock Exchange |
| Fiscal Year | January - December |
| Reporting Currency | PLN |
| ISIN Number | PLBCLTX00019 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Lukasz Bzdzion | Chief Executive Officer and President of the Management Board |
| Dr. Pawel Wielgus Eng., Ph.D. | Member of the Management Board |
| Andrij Wlach | Chief Financial Officer |
| Grzegorz Ostropolski | Chief Operating Officer |
| Lahoud Touma | Director of Technology |
| Jakub Wacek | Legal Counsel and General Counsel |
| Dr. Patryk Reniewicz Ph.D. | Head of Research & Development and Leader of the In Vitro Diagnostics Development Team |
| Agnieszka Kielczykowska | Head of Procurement and Supply |
| Anna Olko-Chudy | Head of the Management Office and Tissue Coordinator |
| Katarzyna Wroblewska | Head of Quality Assurance |